Biogen Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIOGEN INC, and what generic alternatives to BIOGEN INC drugs are available?
BIOGEN INC has three approved drugs.
There are seventeen US patents protecting BIOGEN INC drugs.
There are two hundred and sixteen patent family members on BIOGEN INC drugs in forty-two countries and forty-six supplementary protection certificates in thirteen countries.
Summary for Biogen Inc
International Patents: | 216 |
US Patents: | 17 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
PTAB Cases with Biogen Inc as patent owner: | See PTAB cases with Biogen Inc as patent owner |
Drugs and US Patents for Biogen Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | AB | RX | Yes | No | 10,959,972 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | AB | RX | Yes | No | 10,555,993 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | AB | RX | Yes | Yes | 10,391,160 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Biogen Inc | ZURZUVAE | zuranolone | CAPSULE;ORAL | 217369-001 | Oct 31, 2023 | RX | Yes | No | 9,512,165 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | AB | RX | Yes | No | 8,399,514 | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Biogen Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 8,524,773 | ⤷ Try a Trial |
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-002 | Mar 27, 2013 | 6,509,376 | ⤷ Try a Trial |
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | 7,619,001 | ⤷ Try a Trial |
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | 6,509,376 | ⤷ Try a Trial |
Biogen Inc | TECFIDERA | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 204063-001 | Mar 27, 2013 | 8,759,393 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BIOGEN INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-releaseCapsules | 120 mg and 240 mg | ➤ Subscribe | 2017-03-27 |
International Patents for Biogen Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 102085557 | ⤷ Try a Trial |
Russian Federation | 2015149008 | ⤷ Try a Trial |
European Patent Office | 3981763 | ⤷ Try a Trial |
Australia | 2020256400 | ⤷ Try a Trial |
China | 115501218 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Biogen Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1131065 | C300675 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DIMETHYLFUMARAAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130 |
1131065 | CA 2014 00036 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DIMETHYL FUMARAT (DIMETHYLFUMARAT); REG. NO/DATE: EU/1/13/837/001-002 20140130 |
0605697 | SPC/GB01/008 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 |
2441753 | SPC/GB17/036 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ALECTINIB (9-ETHYL-6,6-DIMETHYL-8-(4-MORPHOLIN-4-YL-PIPERIDIN-1-YL)-11-OXO-6,11-DIHYDRO-5H-BENZO(B)CARBAZOLE-3-CARBONITRILE) OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/16/1169 (NI) 20170220; UK PLGB 00031/0843 20170220 |
0300652 | SPC/GB03/005 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: D-MEDETOMIDINE (4-((1S)-1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE) AND ITS NON-TOXIC PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE HYDROCHLORIDE; REGISTERED: UK EU/2/02/033/001 20020830 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.